Healthcare decisions are inherently agonizing, and in the United States, this agony is compounded by the uncertainty of what will or will not be covered by insurance.
The Trial, which is expected to begin in December 2024, will evaluate the immunogenicity and safety of the YSJA rabies vaccine across two distinct four-dose immunization schedules to determine ...